Comparative efficacy and safety of immunomodulatory therapies for sepsis: a systematic review and network meta-analysis - Takeaways - MDSpire

Comparative efficacy and safety of immunomodulatory therapies for sepsis: a systematic review and network meta-analysis

  • By

  • Rong Luo

  • Shunyao Xu

  • Yuting Chen

  • Zhenmi Liu

  • Xiaofan Deng

  • Chenxi Li

  • Kangping Hui

  • Youlian Chen

  • Chengying Hong

  • ChunBo Chen

  • Huaisheng Chen

  • May 12, 2026

  • 0 min

Share

  • 1

    The systematic review included 76 randomized controlled trials with 22,194 patients to compare immunomodulatory treatments for sepsis.

  • 2

    Ulinastatin demonstrated the most significant reduction in all-cause mortality among the treatments evaluated.

  • 3

    Combination therapies involving ulinastatin and thymosin-α1 showed reduced ICU length of stay and mechanical ventilation duration.

  • 4

    Polyunsaturated fatty acids (PUFA) were effective in shortening hospital length of stay and were associated with fewer serious adverse events.

  • 5

    The study highlights the need for large-scale RCTs to validate findings and improve clinical guidelines for sepsis treatment.

Original Source(s)

Comparative efficacy and safety of immunomodulatory therapies for sepsis: a systematic review and network meta-analysis

  • by Rong Luo, Shunyao Xu, Yuting Chen, Zhenmi Liu, Xiaofan Deng, Chenxi Li, Kangping Hui, Youlian Chen, Chengying Hong, ChunBo Chen, Huaisheng Chen

  • May 12, 2026

Related Content

The prognostic value of the CALLY index in sepsis: a systematic review and meta-analysis

Multi-cohort transcriptomics integration for building and validating a diagnostic model of peripheral blood septic shock

Case Report: Severe sepsis due to imported scrub typhus in a German traveler returning from Vietnam